VTU´s Pichia pastoris platform is a high productivity system for the manufacture of recombinant albumins and albumin fusion proteins.
This technology has yielded titers of up to 35 g/L of recombinant albumins, thus constituting the highest values so far reported with respect to recombinant proteins being secreted into the culture supernatant of yeast cultivations.
The use of a special subset of VTU´s exclusive AOX1 promoter variants, enabling production processes without the need for induction with methanol, furnishes double-digit g/L levels of HSA in fermentations with glycerol as the sole carbon source.Benefits
The suite of exclusive technologies making up VTU´s Pichia production platform stands out for its high-performance expression strains and corresponding processes enabling significantly more cost effective production of customer´s HSA fusion proteins.
Compared with alternative technologies, such as PEGylation, Pichia-produced recombinant albumin fusion requires no post-expression chemical modifications and hence fewer purification steps.
VTU Technology has successfully applied recombinant albumin fusion technology to various proteins and peptides. Albiglutide, a dimer of a recombinant glucagon-like peptide-1 variant fused to human albumin ((GLP-1)-(GLP-1)-HSA) has recently obtained US FDA (Tanzeum) and EMA (Eperzan) approvals. Various other proteins and peptides fused to HSA are in clinical and pre-clinical development.
Click on albumin fusion proteins for other information.